- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07259681
Microbiome intestinal chez les patientes atteintes de cancer gynécologique avec toxicité pelvienne : comparaison avec des témoins et effet de l'ozone rectal. (MicrOzoGineTox). (MicrOGineTox)
Profils du microbiote intestinal chez les femmes atteintes de tumeurs gynécologiques et de toxicité pelvienne secondaire à la radiothérapie et à la chimiothérapie : comparaison avec des témoins et effet d'un traitement rectal à l'ozone.
Patients treated for gynecological tumors with radiotherapy (RT) and/or chemotherapy (CT) frequently develop pelvic toxicity (TPIRQT), a condition that can become persistent, progressive, and refractory to standard treatments. This toxicity, affecting the rectum (proctitis), bladder (cystitis), and vagina (mucositis), severely deteriorates quality of life. Standard options for refractory cases are limited; at our center, rectal ozone therapy is used with high rates of symptomatic improvement (66-75%). Emerging evidence suggests a link between gut microbiota and the development of TPIRQT. However, it is unknown how rectal ozone therapy may influence the gut microbiome or if this modulation is part of its therapeutic mechanism. This prospective observational study will investigate the potential relationship between gut microbiome profiles (composition and diversity), the presence and severity of TPIRQT, and the response to rectal ozone therapy.
Aperçu de l'étude
Statut
Description détaillée
Patients treated for gynecological tumors with radiotherapy (RT) and/or chemotherapy (CT) frequently develop pelvic toxicity (TPIRQT), a condition that can become persistent, progressive, and refractory to standard treatments. This toxicity, affecting the rectum (proctitis), bladder (cystitis), and vagina (mucositis), severely deteriorates quality of life. Standard options for refractory cases are limited; at our center, rectal ozone therapy is used with high rates of symptomatic improvement (66-75%). Emerging evidence suggests a link between gut microbiota and the development of TPIRQT. However, it is unknown how rectal ozone therapy may influence the gut microbiome or if this modulation is part of its therapeutic mechanism. This prospective observational study will investigate the potential relationship between gut microbiome profiles (composition and diversity), the presence and severity of TPIRQT, and the response to rectal ozone therapy.
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Bernardino Clavo, MD, PhD
- Numéro de téléphone: 34928449278
- E-mail: bernardinoclavo@gmail.com
Sauvegarde des contacts de l'étude
- Nom: Francisco Rodríguez-Esparragón, BSc, PhD
- Numéro de téléphone: 34928449288
- E-mail: afrodesp@gmail.com
Lieux d'étude
-
-
Las Palmas
-
Las Palmas de Gran Canaria, Las Palmas, Espagne, 35019
- Recrutement
- Hospital Universitario de Gran Canaria Dr. Negrín, (FIISC)
-
Contact:
- Bernardino Clavo, MD, PhD
- Numéro de téléphone: 34928449278
- E-mail: bernardinoclavo@gmail.com
-
Contact:
- Francisco Rodríguez-Esparragón, BSc, PhD
- Numéro de téléphone: 34928449288
- E-mail: afrodesp@gmail.com
-
-
Tenerife
-
San Cristóbal de La Laguna, Tenerife, Espagne, 38296
- Recrutement
- Instituto Universitario de Enfermedades Tropicales y Salud Pública de Canarias - Universidad de La Laguna
-
Contact:
- Jacob Lorenzo-Morales, Prof
- Numéro de téléphone: 34922318402
- E-mail: jmlorenz@ull.edu.es
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
Patients with gynecological tumors treated with RT and/or CT with or without chronic pelvic toxicity (TPIRQT).
La description
Inclusion Criteria for all patients (Cases and Controls):
-
Adult women (>=18 years).
-
Diagnosed with gynecological tumors (any location and stage).
-
Previously treated with radiotherapy and/or chemotherapy.
-
Must accept and sign the specific informed consent for this study.
Additional Inclusion Criteria for inclusion in the TPIRQT Group (Cases):
-
Must present chronic TPIRQT with >= 3 months of duration after habitual symptomatic treatment.
-
Must have a toxicity Grade of 2 (moderate symptoms, limiting instrumental ADL) or higher, according to the CTCAE v.5.0 scale.
Exclusion Criteria for all patients (Cases and Controls):
- Not meeting all inclusion criteria.
- Presence of active inflammatory bowel disease (e.g., Crohn's Disease, Ulcerative Colitis) or a history of major gastrointestinal resection (excluding appendectomy) that could significantly alter gut anatomy and microbiota.
- Any uncontrolled intercurrent illness or psychiatric condition that, in the investigator's opinion, would limit compliance with study requirements or interfere with the interpretation of results.
- Unwillingness or inability to provide written informed consent for study participation.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: CASE_CONTROL
- Perspectives temporelles: PROSPECTIVE
Cohortes et interventions
Groupe / Cohorte |
|---|
|
TPIRQT Group (Cases)
Patients with gynecological tumors treated with RT and/or CT who develop chronic pelvic toxicity (TPIRQT) and are referred for compassionate-use rectal ozone therapy at the Chronic Pain Unit. Samples and data will be collected before and after ozone therapy |
|
Control Group
pelvic toxicity (TPIRQT). This group will be matched by age (± 5 years) and primary tumor location. Samples and data will be collected once during a follow-up visit. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Comparison of gut microbiome profile (composition and diversity) between TPIRQT and Control groups
Délai: Baseline (single time point for controls, pre-ozone for cases)
|
Gut microbiome composition and diversity (from a single sample) in control patients will be compared to the baseline profile of patients with TPIRQT. |
Baseline (single time point for controls, pre-ozone for cases)
|
|
Change in gut microbiome profile (composition and diversity) in patients with TPIRQT after rectal ozone therapy.
Délai: Baseline (pre-ozone therapy) , 4 Months (post-ozone therapy)
|
Gut microbiome composition and diversity will be analyzed from stool samples using 16S ribosomal RNA gene sequencing. |
Baseline (pre-ozone therapy) , 4 Months (post-ozone therapy)
|
|
Correlation of gut microbiome profile with grade of pelvic toxicity.
Délai: Baseline (for Control group); Baseline, 4 Months (for TPIRQT group).
|
Toxicity will be assessed using: i) the CTCAE v.5.0 scale from the NCI , and ii) the EORTC QLQ-CX24 questionnaire. This will be evaluated for its relationship to microbiome data. |
Baseline (for Control group); Baseline, 4 Months (for TPIRQT group).
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Correlation of gut microbiome profile with health-related quality of life (HRQoL).
Délai: Baseline (for Control group); Baseline, 4 Months (for TPIRQT group).
|
HRQoL will be assessed using: i) the EQ-5D-5L questionnaire, and ii) the EORTC QLQ-C30 questionnaire. This will be evaluated for its relationship to microbiome data. |
Baseline (for Control group); Baseline, 4 Months (for TPIRQT group).
|
|
Correlation of gut microbiome profile with anxiety and depression levels.
Délai: Baseline (for Control group); Baseline, 4 Months (for TPIRQT group).
|
Anxiety and depression will be assessed using the Hospital Anxiety and Depression Scale (HADS). This will be evaluated for its relationship to microbiome data. |
Baseline (for Control group); Baseline, 4 Months (for TPIRQT group).
|
|
Correlation of gut microbiome profile with biochemical markers of oxidative stress and inflammation.
Délai: Baseline (for Control group); Baseline, 4 Months (for TPIRQT group).
|
Serum samples will be collected to analyze biochemical parameters of oxidative stress and inflammation and their potential relationship with gut microbiome composition. |
Baseline (for Control group); Baseline, 4 Months (for TPIRQT group).
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chaise d'étude: Bernardino Clavo, MD, PhD, Hospital Universitario de Gran Canaria Dr. Negrín, (FIISC), Las Palmas, Spain
- Chercheur principal: Francisco Rodríguez-Esparragón, BSc, PhD, Hospital Universitario de Gran Canaria Dr. Negrín, (FIISC), Las Palmas, Spain
- Chercheur principal: Jacob Lorenzo-Morales, Prof, Instituto Universitario de Enfermedades Tropicales y Salud Publica de Canarias, Universidad La Laguna
Publications et liens utiles
Publications générales
- Wang A, Ling Z, Yang Z, Kiela PR, Wang T, Wang C, Cao L, Geng F, Shen M, Ran X, Su Y, Cheng T, Wang J. Gut microbial dysbiosis may predict diarrhea and fatigue in patients undergoing pelvic cancer radiotherapy: a pilot study. PLoS One. 2015 May 8;10(5):e0126312. doi: 10.1371/journal.pone.0126312. eCollection 2015.
- Wang L, Wang X, Zhang G, Ma Y, Zhang Q, Li Z, Ran J, Hou X, Geng Y, Yang Z, Feng S, Li C, Zhao X. The impact of pelvic radiotherapy on the gut microbiome and its role in radiation-induced diarrhoea: a systematic review. Radiat Oncol. 2021 Sep 25;16(1):187. doi: 10.1186/s13014-021-01899-y.
- Clavo B, Navarro M, Federico M, Borrelli E, Jorge IJ, Ribeiro I, Rodriguez-Melcon JI, Carames MA, Santana-Rodriguez N, Rodriguez-Esparragon F. Long-Term Results with Adjuvant Ozone Therapy in the Management of Chronic Pelvic Pain Secondary to Cancer Treatment. Pain Med. 2021 Sep 8;22(9):2138-2141. doi: 10.1093/pm/pnaa459. No abstract available.
- Clavo B, Navarro M, Federico M, Borrelli E, Jorge IJ, Ribeiro I, Rodriguez-Melcon JI, Carames MA, Santana-Rodriguez N, Rodriguez-Esparragon F. Ozone Therapy in Refractory Pelvic Pain Syndromes Secondary to Cancer Treatment: A New Approach Warranting Exploration. J Palliat Med. 2021 Jan;24(1):97-102. doi: 10.1089/jpm.2019.0597. Epub 2020 May 5.
- Clavo B, Ceballos D, Gutierrez D, Rovira G, Suarez G, Lopez L, Pinar B, Cabezon A, Morales V, Oliva E, Fiuza D, Santana-Rodriguez N. Long-term control of refractory hemorrhagic radiation proctitis with ozone therapy. J Pain Symptom Manage. 2013 Jul;46(1):106-12. doi: 10.1016/j.jpainsymman.2012.06.017. Epub 2012 Oct 26.
- Clavo B, Canovas-Molina A, Ramallo-Farina Y, Federico M, Rodriguez-Abreu D, Galvan S, Ribeiro I, Marques da Silva SC, Navarro M, Gonzalez-Beltran D, Diaz-Garrido JA, Cazorla-Rivero S, Rodriguez-Esparragon F, Serrano-Aguilar P. Effects of Ozone Treatment on Health-Related Quality of Life and Toxicity Induced by Radiotherapy and Chemotherapy in Symptomatic Cancer Survivors. Int J Environ Res Public Health. 2023 Jan 13;20(2):1479. doi: 10.3390/ijerph20021479.
- Clavo B, Santana-Rodriguez N, Llontop P, Gutierrez D, Ceballos D, Mendez C, Rovira G, Suarez G, Rey-Baltar D, Garcia-Cabrera L, Martinez-Sanchez G, Fiuza D. Ozone Therapy in the Management of Persistent Radiation-Induced Rectal Bleeding in Prostate Cancer Patients. Evid Based Complement Alternat Med. 2015;2015:480369. doi: 10.1155/2015/480369. Epub 2015 Aug 18.
- Li L, Yang Z, Yi Y, Song Y, Zhang W. Gut microbiota and radiation-induced injury: mechanistic insights and microbial therapies. Gut Microbes. 2025 Dec;17(1):2528429. doi: 10.1080/19490976.2025.2528429. Epub 2025 Jul 6.
- Ma CY, Zhao J, Xu XT, He XL, Qin SB, Zhou JY. Predictive biomarkers in the gut microbiome and metabolome for severe acute radiation enteritis in cervical cancer radiotherapy. Discov Oncol. 2025 Jul 1;16(1):1220. doi: 10.1007/s12672-025-03077-y.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 2025-436-1
- PIFIISC25/52 (Autre subvention/numéro de financement: FIISC (Fundación Canaria Inst. Investig. Sanitaria Canarias))
- CIGC'25/26 (Autre subvention/numéro de financement: Cabildo de Gran Canaria (CIGC))
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
- It will be available (after request): Individual participant data (IPD) that underlie the results reported in further articles, after deidentification
- Data will be available after publication, ending 36 months following article publication.
- They will be available for investigators whose proposed use of the data has been apd by an independent review committee identified for this purpose.
Délai de partage IPD
Data will be available after publication, ending 36 months following article publication.
Critères d'accès au partage IPD
They will be available for investigators whose proposed use of the data has been approved by an independent review committee identified for this purpose
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .